Needham Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $200
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Joseph Stringer has maintained a 'Buy' rating on Alnylam Pharmaceuticals (NASDAQ:ALNY), but lowered the price target from $240 to $200.
October 09, 2023 | 4:10 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Alnylam Pharmaceuticals' price target has been lowered from $240 to $200 by Needham, though the 'Buy' rating is maintained.
The news is directly about Alnylam Pharmaceuticals and is likely to impact investor sentiment. While the 'Buy' rating is maintained, the lowering of the price target may indicate a perceived decrease in the company's short-term growth potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100